Chinese Oncology Drugmaker to Raise over 600 Million in Hong Kong IPO
After finishing the rolling submission of its oncology drug’s New Drug Application (NDA), China’s Hutchmed files for its first Initial Public Offering (IPO) on the Hong Kong Stock Exchange (HKEX), …
Read More